Therapeutic Effect of Umbilical Cord Serum Eyedrops for Persistent Corneal Epithelial Defect

Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease

“…10,12 Recently, several studies have been reported on the beneficial effect of 20% umbilical cord serum eyedrops in the treatment of dry eye syndrome and persistent epithelial defect of the cornea. 10,11,19 Umbilical cord serum led to faster healing of persistent corneal epithelial defects refractory to medical treatment compared to autologous serum. 19 Compared with autologous serum, umbilical cord serum has several advantages to treat dry eye associated with GVHD.…”

“…[7][8][9] Recently, we found that umbilical cord serum also contains many growth factors and essential tear components, and umbilical cord serum eyedrops are safe and effective for treating dry eye syndrome and persistent epithelial defect. [10][11] In the present study, we prospectively investigated the therapeutic effect of umbilical cord serum eyedrops on severe dry eye associated with GVHD.…”

Open Clinical Study of Eye Drops Containing the Fibronectin-Derived Peptide PHSRN for Treatment of Persistent Corneal Epithelial Defects

“…Four of the 7 eyes showed more than 40% wound healing at 3 days after treatment initiation, and these eyes manifested complete wound closure within 28 days. The epithelial defects healed at 17,68,11,17,20,44, and 14 days after treatment initiation for subjects 1 to 7, respectively. Overall, 5 of the 7 PED cases (71%) were treated successfully with PHSRN eye drops, with the mean ± SD time for complete resurfacing being 15.8 ± 3.4 days in these 5 individuals (subjects 1, 3, 4, 5, and 7).…”

“…6 Such treatment is passive in nature in that it does not stimulate corneal epithelial wound healing but rather protects the corneal surface from external stimuli or injuries until complete wound healing. Active treatment to stimulate corneal epithelial migration in eyes with PEDs is a preferable therapeutic approach, and some success in this regard has been achieved with the application of nerve growth factor, 7,8 fibronectin, 9,10 umbilical cord serum, 11,12 autologous serum, [13][14][15] or the combination of substance P plus insulin-like growth factor (IGF)-1 (or peptides corresponding to minimal essential sequences thereof). [16][17][18][19] However, no active treatment regimen for PEDs has yet become widely established.…”

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

“…In addition, administration of artificial tears, viscoelastic (such as hyaluronan or chondroitin sulfate) eyedrops, punctal plugs (Tai et al, 2002), and fibrin glue (Sumich et al, 2003) as well as improved lid hygiene have been tried. Autologous serum eyedrops (Geerling et al, 2004;Matsumoto et al, 2004;Mukerji et al, 2002;Noble et al, 2004), umbilical cord serum (Vajpayee et al, 2003;Yoon et al, 2005Yoon et al, , 2007, EGF (Daniele et al, 1992), and plasma rich in growth factors (Cho et al, 2013;Geerling et al, 2004;Kim et al, 2012;Lopez-Plandolit et al, 2010;Mukerji et al, 2002;Poon et al, 2001;Tsubota et al, 1999b;Vajpayee et al, 2003) have also been examined in the clinical setting, but none of these treatment modalities has been confirmed to be effective scientifically (Pan et al, 2013).…”